周剂量顺铂胸腔灌注联合复方苦参注射液治疗非小细胞肺癌并恶性胸腔积液的临床研究

Clinical research on weekly -dose of cisplatin intrapleural infusion combined with Compound Kushen Injection in treatment of non-small cell lung cancer complicating malignant pleural effusion

目的评价周剂量顺铂胸腔灌注联合复方苦参注射液治疗非小细胞肺癌伴胸腔积液患者的疗效和安全性。方法将93例非小细胞肺癌伴胸腔积液患者随机分为常规组和观察组。常规组在常规治疗基础上加顺铂和地塞米松胸腔灌注,观察组在常规组治疗基础上加复方苦参注射液静脉滴注。评价两组患者疗效和安全性。结果观察组近期疗效与Karnofsky评分改善优于常规组,骨髓抑制作用和肝功能损害低于常规组,差异均有统计学意义(P<0.05或0.01)。结论复方苦参注射液协同顺铂可提高非小细胞肺癌患者胸腔积液的疗效,不良反应少,值得临床推广应用。

Objective To evaluate the effect and safety of weekly-dose of cisplatin intrapleural infusion combined with Compound Kushen Injection in treating non-small cell lung cancer（NSCLS） complicating malignant pleural effusion. Methods 93 patients with NSCLS complicating malignant pleural effusion were randomly divided into the routine group and the observation group. The routine group was added with cisplatin and dexamethasone by intrapleural infusion on the basis of conventional thera- py, and the observation group was added with Compound Kushen Injection by intravenous drip on the basis of the routine group. The efficacy and safety were evaluated in both groups. Results The short term efficacy and the improvement of the Karnofsky scores in the observation group was superior to that in the routine group;the degree of bone marrow suppression and the liver function damage in the observation group were lower than those in the control group, the differences between the two groups all had statistical significance （P〈0.05 or 0.01 ）. Conclusion Compound Kushen Injection is synergistic with cisplatin to improve the curative efficacy in treating NSCLS complicating malignant pleural effusion with few adverse reactions ,which is worthy of clinical promotion.